Cabanillas ME et al. -Sorafenib and lenvatinib are approved for radioiodine (RAI)-refractory differentiated thyroid cancer (DTC); however, no second- or third-line therapies have been approved. In the current study, cabozantinib was shown to yield clinically significant, durable objective response activity in patients with RAI-refractory DTC with disease progression while on VEGFR-targeted therapy.